Cryoport, INC Form 4 insider transactions

Jerrell Shelton, President, CEO and a Director of Cryoport, Inc., sold 28,800 shares of common stock on August 11, 2026 for $14.91 per share.

Chief Digital and Tech Officer Edward J. Zecchini exercised options and sold 35,000 shares of Cryoport, Inc. common stock.

Cryoport, Inc. Director Linda Baddour acquired 10,350 shares of common stock and was granted options for 16,077 shares.

Cryoport, Inc. Chief Financial Officer Robert Stefanovich sold 169,427 shares of common stock on June 4, 2026.

Director Daniel M. Hancock acquired 10,350 shares of restricted stock and 16,077 stock options in Cryoport, Inc.

Director Robert J. Hariri acquired 10,350 shares of restricted stock and 16,077 stock options in Cryoport, Inc.

Cryoport, Inc. Director Ramkumar Mandalam reported the acquisition of restricted stock and the sale of common shares in a recent SEC Form 4 filing.

Cryoport CEO Jerrell Shelton acquired 104,007 shares of common stock through the exercise of stock options.

Cryoport, Inc. CEO Jerrell Shelton acquired 50,000 shares of common stock on April 6, 2026, at a price of $1.87 per share.

Cryoport's Chief Financial Officer, Robert Stefanovich, sold 1,094 shares of common stock to cover tax obligations related to restricted stock vesting.

Cryoport's President and CEO, Jerrell Shelton, reported the exercise of options for 25,000 common shares and the sale of 2,894 shares to cover tax obligations.

Cryoport's Chief Scientific Officer, Mark W. Sawicki, sold 1,341 shares of common stock to cover tax obligations related to restricted stock vesting.

Cryoport's Chief Digital and Technology Officer, Edward J. Zecchini, reported the acquisition of restricted stock rights and stock options, alongside a sale of shares to cover tax obligations.

Cryoport's President and CEO, Jerrell Shelton, reported the sale of 7,918 common shares for tax purposes and the acquisition of 492,901 stock options.

Cryoport's Chief Scientific Officer, Mark W. Sawicki, reported the acquisition of restricted stock rights and stock options, alongside a tax-related sale of common stock.

Cryoport's Chief Financial Officer, Robert Stefanovich, reported exercising stock options and selling shares to cover associated taxes and exercise costs.

Cryoport Director Ramkumar Mandalam reported the sale of 11,570 shares of common stock for approximately $115,550 under a Rule 10b5-1 plan.

Cryoport Director Robert J. Hariri exercised stock options and subsequently sold a portion of the acquired shares to cover costs.

Cryoport Director Robert J. Hariri sold 5,000 shares of common stock at $8.60 per share, reducing his direct beneficial ownership to 26,275 shares.

Cryoport's Chief Financial Officer, Robert Stefanovich, exercised stock options and subsequently sold a portion of the acquired shares to cover the exercise cost.

Cryoport's President and CEO, Jerrell Shelton, exercised 25,000 stock options at $5 per share, increasing his direct beneficial ownership without selling shares.

Cryoport Inc. President and CEO Jerrell Shelton exercised 25,000 stock options at $5 per share, increasing his direct beneficial ownership.

Cryoport, Inc.'s President and CEO, Jerrell Shelton, exercised stock options to acquire 25,000 shares of common stock at $5 per share, increasing his direct beneficial ownership without subsequent sale.

Cryoport Inc. Director Ramkumar Mandalam exercised stock options and sold a portion of the resulting common stock on July 22, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Cryoport's President and CEO, Jerrell Shelton, exercised stock options to acquire 25,000 shares of common stock, significantly increasing his direct beneficial ownership.

Cryoport, Inc. CEO Jerrell Shelton exercised 25,000 stock options at $5 per share, increasing his direct beneficial ownership of common stock to 962,419 shares.

Cryoport, Inc. CEO and Director Jerrell Shelton reported the exercise of stock options and subsequent sale of shares, along with an additional option exercise, all executed under a pre-arranged trading plan.

A director at Cryoport, Inc. executed a pre-planned transaction, exercising stock options and subsequently selling a portion of the acquired common stock.

Cryoport Inc.'s President and CEO, Jerrell Shelton, exercised stock options and subsequently sold a portion of the acquired common stock through a pre-arranged 10b5-1 trading plan in mid-June 2025.

Cryoport, Inc. Director Ramkumar Mandalam has reported the sale of 10,712 shares of common stock over three days in June 2025, reducing his beneficial ownership to 66,377 shares.